



# Bio Engineered Bacteria for Cancer Treatment


Paola Argumedo, Renate De Vreede,  
Gábor Kovács, Kassian Armbruster

22 March 2022




# Topics of Discussion


- Problem Definition
- Treatment
- *E.coli* genetic engineering
- BioBricks design




# Problem Definition



[1]





[2]





[3]

# Interleukin-2 (Aldesleukin)



# E. coli



# Biobrick design

How does the system work?


- Inputs: hypoxia and high lactate
- Output: Aldeslukin (treatment)

The treatment gene is in constant repression by 2 different proteins, and our inputs cancel the repression state.




# Truth table and circuit design

Lactate	Hypoxia	Output
0	0	0
1	0	0
0	1	0
1	1	1




# Hypoxia state circuit





# Lactate circuit




# Final plasmid Design

- Cloned on pUC19 vector
- totalling 8004 bp
- Common for E. coli
- With Amp resistance
- 54 bp multiple cloning site polylinker




# GCF\_000001405.39 or TETRAN

- Human Tetracycline
- Encodes a member of the major facilitator superfamily of transporter proteins
- Efflux of organic anions, including the non-steroidal anti-inflammatory drugs indomethacin and diclofenac



# promoter of LldR


- Natural promoter with 2 operators
- It regulates the expression of the *lldPRD* operon
- Involved in L-lactate metabolism



[4] [http://parts.igem.org/Part:BBa\\_K1847008](http://parts.igem.org/Part:BBa_K1847008)

# promoter TetR

Based on regulatory elements that control the activity of the tetracycline-resistance operon




[5] <https://dx.doi.org/10.2174%2F1566523216666160524144041>

# Other promoters

Usually used in E. coli vectors to produce GFP


- Promoter SrpR
  - 5000 RFU
- Promoter PhIF
  - Consecutive promoters family
- Promoter J23100
  - 2 different RBS
  - 10000 RFU



# HlyA signal peptide

Carried by alpha-hemolysin extracellular media export system

- HlyB
- HlyD
- TolC





**Thank you  
for your  
attention**



# References

- Zhou, S. et al. (2018). Tumour-targeting bacteria engineered to fight cancer. *Nature Reviews Cancer*, 18, 727-743.
- Yang, L. V. (2017). Tumor Microenvironment Metabolism. *International Journal of Molecular Sciences*, 18(12).
- Jiang, B. (2017). Aerobic glycolysis and high level concentration of lactate in cancer metabolism and microenvironment. *Genes & Diseases*, 14;4(1), 25-27.
- Thomas, S., Barry Holland, I., Schmitt, L. (2014). The Type 1 secretion pathway- the hemolysin system and beyond. *Biochimica et Biophysica Acta*, 1843, 1629-1641
- Das, A. T., Tenenbaum, L., & Berkhout, B. (2016). Tet-on systems for doxycycline-inducible gene expression. *Current Gene Therapy*, 16(3), 156–167. <https://doi.org/10.2174/1566523216666160524144041>
- New England Biolabs. (s/f). *PUC19 vector*. Neb.Com. Recovered march 2022, de <https://international.neb.com/products/n3041-puc19-vector>
- *Part:BBa\_K3320006* - *parts.Igem.Org.* (s/f). Igem.Org. Recovered march 2022, de [http://parts.igem.org/Part:BBa\\_K3320006](http://parts.igem.org/Part:BBa_K3320006)
- *Homo sapiens chromosome 4, GRCh38.p13 Primary Assembly - Nucleotide - NCBI.* (n.d.). Nih.Gov. Retrieved March 25, 2022, from [https://www.ncbi.nlm.nih.gov/nucleotide/NC\\_000004.12?report=genbank&from=122451470&to=122456725&strand=true](https://www.ncbi.nlm.nih.gov/nucleotide/NC_000004.12?report=genbank&from=122451470&to=122456725&strand=true)
- *Team:Amazonas-Brazil/description.* (n.d.). Igem.Org. Retrieved March 25, 2022, from <https://2019.igem.org/Team:Amazonas-Brazil/Description>
- <https://www.ncbi.nlm.nih.gov/gene/10227>